At UEG Week Berlin, experts highlighted key advances in cirrhosis management.

Sarcopenia: Affects approximately 40% of patients with cirrhosis; assess patients regularly using the liver frailty index. Gut dysbiosis and myostatin upregulation drive muscle loss. Prevention focuses on nutrition, exercise, and possible testosterone therapy.

Portal Vein Thrombosis: Common in advanced disease; anticoagulation (LMWH or DOACs) improves survival and recanalization without raising bleeding risk. Use DOACs, cautiously in Child B/C, recommended researchers. TIPS remains effective for refractory cases.

Hepatorenal Syndrome: Now viewed as partly structural and inflammatory. Terlipressin plus albumin remains first-line therapy but requires close hemodynamic monitoring. Early AKI detection and urinary biomarkers may help guide therapy and reduce readmissions.

Source: UEG Week 2025